Salud

Dos píldoras prometen llenar vacíos en lucha contra la covid-19

Los laboratorios Pfizer y MSD ya presentaron resultados de sus ensayos clínicos ¿para qué un tratamiento oral cuándo ya hay vacunas? ‘La Nación’ lo explora

This October 18, 2021 handout photo courtesy of Merck & Co,Inc. shows capsules of the antiviral pill Molnupiravir. - Britain on November 4, 2021, approved the use of Merck's antiviral pill to treat patients suffering from mild to moderate Covid-19, the Medicines and Healthcare products Regulatory Agency (MHRA) announced. "Today is a historic day for our country, as the UK is now the first country in the world to approve an antiviral that can be taken at home for Covid-19," said health minister Sajid Javid. Molnupiravir, works by decreasing the ability of a virus to replicate, thereby slowing down the disease. (Photo by Handout / Merck & Co,Inc. / AFP) / RESTRICTED TO EDITORIAL USE - MANDATORY CREDIT "AFP PHOTO /Merck & Co,Inc./HANDOUT" - NO MARKETING - NO ADVERTISING CAMPAIGNS - DISTRIBUTED AS A SERVICE TO CLIENTS
This October 18, 2021 handout photo courtesy of Merck & Co,Inc. shows capsules of the antiviral pill Molnupiravir. - Britain on November 4, 2021, approved the use of Merck's antiviral pill to treat patients suffering from mild to moderate Covid-19, the Medicines and Healthcare products Regulatory Agency (MHRA) announced. "Today is a historic day for our country, as the UK is now the first country in the world to approve an antiviral that can be taken at home for Covid-19," said health minister Sajid Javid. Molnupiravir, works by decreasing the ability of a virus to replicate, thereby slowing down the disease. (Photo by Handout / Merck & Co,Inc. / AFP) / RESTRICTED TO EDITORIAL USE - MANDATORY CREDIT "AFP PHOTO /Merck & Co,Inc./HANDOUT" - NO MARKETING - NO ADVERTISING CAMPAIGNS - DISTRIBUTED AS A SERVICE TO CLIENTS HANDOUT
‌
‌

‌

‌
‌

‌

‌